Literature DB >> 26273341

Mouse double minute-2 homolog (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese population.

Xu Wang1, Lina Jin2, Jiuwei Cui1, Kewei Ma1, Xiao Chen1, Wei Li1.   

Abstract

BACKGROUND: Altered expression or function of mouse double minute-2 (MDM2) protein could contribute to lung carcinogenesis; thus, this study investigated MDM2-rs2279744 polymorphism together with other epidemiologic factors for their association with lung cancer risk.
METHODS: A total of 500 lung cancer patients and 500 age and gender-matched healthy controls living in Northeastern China were recruited for genotyping of MDM2-rs2279744. Clinicopathological data was collected and subjected to univariate and multivariate analyses.
RESULTS: In univariate analysis, the MDM2-rs2279744 G/G genotype versus T/T + T/G genotypes showed a tendency toward a higher incidence of lung cancer in the recessive model (P = 0.043). However, there were no significant differences when it was analyzed by the dominant, additive, or multiplicative models. A significantly increased lung cancer risk was observed associated with lower education level, lower body mass index, cancer family history, prior diagnosis of chronic obstructive pulmonary disease and pneumonia, exposure to pesticide or gasoline/diesel, tobacco smoking, and heavy cooking emissions when assessed by multivariate analyses. Moreover, MDM2-rs2279744 was still a significant risk factor even after incorporating environmental and lifestyle factors. However, there was no association between MDM2-rs2279744 and other factors.
CONCLUSIONS: The MDM2-rs2279744 G/G genotype was associated with a higher lung cancer risk, even after incorporating other epidemiologic factors.

Entities:  

Keywords:  Chinese population; lung cancer risk; mouse double minute-2 homolog; rs2279744 polymorphism; single nucleotide polymorphism

Year:  2015        PMID: 26273341      PMCID: PMC4448458          DOI: 10.1111/1759-7714.12153

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


Introduction

Lung cancer is one of the most commonly diagnosed malignancies in the world, accounting for 17.6% (1.18 million people) of worldwide cancer-related deaths annually.1 In China, national death survey and cancer registration data shows that lung cancer is also the leading cause of cancer death in most Chinese cities.2 Lung cancer is indeed a major global public health challenge. However, to date, the precise mechanisms of lung carcinogenesis are still not fully understood. A previous study showed that low-penetrance susceptibility genes in combination with environmental factors were of importance in lung cancer development and contributed to lung cancer risk.3 Therefore, further studies in this field could lead to better understanding of lung cancer risk and susceptibility genes. Toward this end, our research focuses on murine double minute-2 (MDM2), which is a negative regulator of p53 tumor suppressor. MDM2 protein functions as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain of p53 protein, and inhibitor of p53 transcriptional activation. MDM2 protein plays an important role in regulation of p53 pathway activity. A single nucleotide polymorphism (SNP) of MDM2-rs2279744 was identified as a functional SNP with a T-to-G transversion and has been proven to increase the affinity of the transcriptional activator Sp1 and lead to expression of higher MDM2 messenger ribonucleic acid (mRNA) and protein levels, subsequently attenuating p53 pathway activity.4 The elevated levels of MDM2 protein in carriers of the G-allele will inhibit the p53-induced apoptotic responses to DNA-damage, thereby resulting in genetic instability (such as gene mutations in the cells) and eventually leading to tumorigenesis at a young age.5 However, the association between MDM2-rs2279744 SNP and lung cancer risk seems plausible; for example, Hu et al.6 and Pine et al.7 reported that there was no significant association between MDM2 SNP309 variant genotypes and lung cancer risk, whereas studies conducted by Zhang et al.8 and Lind et al.9 showed that the G-allele in the MDM2 promoter was associated with a higher lung cancer risk. Additionally, Chua et al. showed that the T-allele in the MDM2 promoter increased lung cancer risk.10 Other studies have demonstrated that MDM2-rs2279744 SNP is associated with lung cancer risk at an early age.11,12 Thus, this case-control study investigated this functionally important MDM2-rs2279744 SNP in our hospital for association with lung cancer risk, together with other clinicopathological and epidemiologic data from lung cancer patients, as other factors, such as sociodemographic information, medical and family history, and lifestyle data, may also play a role in lung carcinogenesis.13–19

Patients and methods

Study population

The study was approved by the Ethics Committee of the First Hospital of Jilin Medical University, and conducted according to the Declaration of Helsinki Principles. All subjects signed a written informed consent form. This hospital-based case-control study recruited a total of 1000 subjects from Northeastern China between January 2010 and December 2012. Patients who met the following criteria were included in the study: (i) a minimum of 18 years of age; (ii) primary lung cancer confirmed by pathology; (iii) Han descent; (iv) reside in Northeastern China for at least 10 years; and (v) no radiotherapy or chemotherapy performed before blood withdrawal. Patients with any of the following conditions were excluded: (i) secondary (metastatic) lung cancer; (ii) double or multiple primary cancers; and (iii) relapse after operation. Healthy controls had no cancer history within five years of the interview date. These healthy controls were randomly selected individuals who received routine physical examinations in our hospital and were matched to cases by age, gender, and residential area.

Diagnostic criteria and data collection

Standardized interviews were conducted by well-trained interviewers at either the hospital or at the homes of the studied subjects. Sociodemographic information, medical and family history, lifestyle data, and cancer diagnosis were recorded (Table 1). Risk factors and peripheral blood lymphocytes were collected for the time prior and up to the index date (i.e. the time of diagnosis for cases and the interview date for controls). However, there were no data available on exposure to asbestos for analysis.
Table 1

Univariate analysis of the risk factors in cases and controls

CharacteristicCase (n = 500 [%])Control (n = 500[%])P-value
GenderMale 305 (61.0) 302 (60.4)0.846
Female 195 (39.0) 198 (39.6)
Age (years)<30  2 (0.4)  5 (1.0)0.421
30–39  14 (2.8)  16 (3.2)
40–49  64 (12.8)  70 (14.0)
50–59 176 (35.2) 196 (39.2)
60–69 174 (34.8) 148 (19.7)
≥70  70 (14.0)  65 (13.0)
EducationJunior high school and lower 318 (63.6) 130 (26.0)0.000
High school  97 (19.4)  144 (28.8)
Greater than high school  85 (17.0)  226 (45.2)
Smoking (pack-years)14.25 (0.0–36.0)0.00 (0.0–6.9)0.000
Occupational exposureAbsent 398 (79.6) 473 (94.6)0.000
PesticidePresent 102 (20.4) 27 (5.4)
Exposure Gasoline /dieselAbsent 487 (97.4) 496 (99.2)0.037
Present  13 (2.6)  4 (0.8)
Exposure to InkAbsent 493 (98.6) 497 (99.4)0.217
Present  7 (1.4)  3 (0.6)
Cooking emissions (total dish-years)Absent 244 (48.8) 250 (50.0)0.003
≤50 149 (29.8) 152 (30.4)
51–100  61 (12.2)  80 (16.0)
101–150  46 (9.2)  18 (3.6)
Pneumonia historyAbsent 477 (95.4) 490 (98.0)0.025
Present  23 (4.6)  10 (2.0)
COPD historyAbsent 449 (89.8) 489 (97.8)0.000
Present  51 (10.2)  11 (2.2)
Pulmonary tuberculosis historyAbsent 470 (94.0) 486 (97.2)0.016
Present  30 (6.0)  14 (2.8)
Bronchial asthma historyAbsent 488 (97.6) 495 (99.0)0.097
Present  12 (2.4)  5 (1.0)
Cancer family historyAbsent 330 (66.0) 397 (79.4)0.000
Present 170 (34.0) 103 (20.6)
BMI (kg/m2)<18.5  49 (9.8)  15 (3.0)0.000
18.5–24 302 (60.4) 230 (46.0)
≥24 149 (29.8) 255 (51.0)

Including large cell, mixed cell carcinoma, or undifferentiated carcinoma. BMI, body mass index; COPD, chronic obstructive pulmonary disease.

Univariate analysis of the risk factors in cases and controls Including large cell, mixed cell carcinoma, or undifferentiated carcinoma. BMI, body mass index; COPD, chronic obstructive pulmonary disease.

Genotyping and quality control

Genomic DNA was extracted from the peripheral blood lymphocytes of all subjects. MassArray (Sequenom, Inc., San Diego, CA, USA) was used for genotyping all markers by using allele specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Primers and multiplex reactions were designed using the RealSNP.com website. All lung cancer patients and healthy controls were genotyped for MDM2-rs2279744 polymorphisms. Concordance among the three genomic control DNA samples presented in duplicate was 100%. Of SNPs with genotyping data, the call rate was >95%.

Statistical analysis

The Hardy-Weinberg equilibrium was performed to analyze the balance of case and control using a goodness-of-fit chi-square (χ2) test. The univariate χ2 test was used to determine genotype frequencies with observed genotype frequencies in healthy controls versus lung cancer cases and association between MDM2-rs2279744 SNP and clinicopathological data from lung cancer patients. Multivariate logistic regression analysis was used to assess the association between risk factors (SNPs were included) and lung cancer risk. All categorical variables were set as dummy variables. The first category of each environmental variable was selected as the baseline, as well as the low-risk allele of each locus. All analysis was conducted using SPSS v19.0 software (SPSS, Inc., Chicago, IL, USA). A p-value of less than 0.05 was considered statistically significant.

Results

Univariate analysis of MDM2-rs2279744 polymorphism for association with lung cancer risk

A total of 1000 subjects (i.e. 500 incident lung cancer cases and 500 healthy controls) were recruited for genotyping of MDM2-rs2279744. Univariate analysis revealed that lung cancer occurred more frequently in individuals with a family history of cancer, history of chronic obstructive pulmonary disease (COPD), pulmonary tuberculosis, pneumonia, low body mass index (BMI), tobacco smoking, occupational exposure to pesticides, gasoline, or diesel, and exposure to cooking emissions, as well as a low education level (Table 1). Furthermore, our data also showed that the genotype distribution of MDM2-rs2279744 polymorphism was followed by Hardy-Weinberg equilibrium (P > 0.05). MDM2 G/G genotype occurred in 25.8%, G/T genotype in 48.8%, and T/T genotype in 25.4% of lung cancer cases, with a similar distribution in the healthy control (P > 0.05). Univariate analysis showed that when comparing G/G with T/T + T/G genotypes, the G/G had a tendency toward a higher incidence of lung cancer in the recessive model (P = 0.043; Table 2). However, there were no significant differences in the dominant, additive, or multiplicative models.
Table 2

Association of MDM2-rs2279744 polymorphism with lung cancer risk analyzed by univariate analysis

GenotypeExp (B)95% CIP-value
Additive modelT/T1Reference
G/T0.932(0.691–1.258)0.645
G/G1.295(0.906–1.849)0.156
Dominant modelT/T1Reference
G/G + G/T1.032(0.777–1.370)0.828
Recessive modelT/T + G/T1Reference
G/G1.357(1.009–1.824)0.043
Multiplicative modelG-allele1.131(0.947–1.351)0.174

CI, confidence interval; MDM2, mouse double minute-2.

Association of MDM2-rs2279744 polymorphism with lung cancer risk analyzed by univariate analysis CI, confidence interval; MDM2, mouse double minute-2.

Multivariate analysis of MDM2-rs2279744 polymorphism for association with lung cancer risk

Multivariate analysis showed a significantly increased lung cancer risk in individuals with a lower education level, lower BMI, cancer family history, prior diagnosis of COPD and pneumonia, exposure to pesticide or gasoline/diesel, tobaccco smoking, heavy cooking smoke, and MDM2-rs2279744 SNP. The latter was still a significant risk factor for lung cancer, even after incorporating environmental and lifestyle factors (Table 3).
Table 3

Multivariate risk model with adjusted odds ratios and 95% CI

Risk factorsExp (B)95% CIP-value
Education level0.000
Junior high school and lower1.00Reference
High school0.3070.211–0.4460.000
Greater than high school0.1950.134–0.2840.000
Smoking (pack-years)1.0321.023–1.0410.000
Occupational exposure to pesticide
Absent1.00Reference
Present1.7001.024–2.8240.040
Exposure to gasoline /diesel
Absent1.00Reference
Present5.0651.430–17.9450.012
Cooking smoke (total dish-years)0.004
≤501.00Reference
51–1001.4170.998–2.0110.869
101–1500.9620.610–1.5190.006
>1502.5111.301–4.8460.026
COPD history
Absent1.00Reference
Present4.1621.950–8.8830.000
Pneumonia history
Present1.00Reference
Absent0.3690.151–0.9020.029
Cancer family history
Absent1.00Reference
Present2.0241.442–2.8420.000
BMI (kg/m2)0.000
<18.51.00Reference
18.5–240.4260.215–0.8430.014
≥240.2150.107–0.4320.000
rs2279744
T/T + G/T1.00Reference
G/G1.4751.153–1.8870.002

BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease.

Multivariate risk model with adjusted odds ratios and 95% CI BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease.

Association of MDM2-rs2279744 SNP with clinicopathological patient data

We also evaluated MDM2-rs2279744 SNP for association with the clinicopathological data from lung cancer patients. We did not find any statistically significant associations (Table 4).
Table 4

Association of MDM2-rs2279744 SNP with the clinicopathological data from lung cancer patients

CharacteristicG/G (n = 231)T/T + G/T (n = 769)P-value
GenderMale1414660.965
Female90303
Age (years)<30340.530
30–39525
40–493698
50–5985287
60–6975247
≥7027108
BMI (kg/m2)<18.58560.101
18.5–24130402
≥2493311
Histology typesSquamous cell351060.946
Adenocarcinoma48128
Small cell3195
Other carcinomas*1542

*Including large cell, mixed cell carcinoma, or undifferentiated carcinoma. BMI, Body mass index; MDM2, mouse double minute-2; SNP, single nucleotide polymorphism.

Association of MDM2-rs2279744 SNP with the clinicopathological data from lung cancer patients *Including large cell, mixed cell carcinoma, or undifferentiated carcinoma. BMI, Body mass index; MDM2, mouse double minute-2; SNP, single nucleotide polymorphism.

Discussion

Several study models have been developed to predict the individual risk for lung cancer using patient characteristics, epidemiologic, social, and clinical risk factors.13–19 Our current study genotyped MDM2-rs2279744 SNP in a Northeastern Chinese population to associate lung cancer risk, together with other clinicopathological and epidemiologic factors. We found that there were several factors associated with lung cancer risk, including family history of cancer, COPD, pneumonia, occupational exposure to pesticide or gasoline/diesel, duration of tobacco smoking, and heavy cooking smoke, as well as lower education level or BMI. Our current data are consistent with the findings of previous studies.13–19 Furthermore, our current study also showed that the MDM2-rs2279744 G/G genotype was associated with lung cancer risk in recessive model analysis and was still associated with lung cancer risk after incorporating environmental and lifestyle factors. Thus, this study has demonstrated that the MDM2-rs2279744 G/G genotype is associated with lung cancer risk. Molecularly, MDM2-rs2279744 is a functional SNP and is able to regulate MDM2 protein expression, that is, the MDM2-rs2279744 G-allele results in higher levels of MDM2 mRNA and protein, which, in turn, attenuate the p53 stress response pathway through directly blocking p53 transcriptional activity and mediating p53 protein degradation.4,20 The attenuation of p53 pathway activity will lead to lung carcinogenesis, which has been confirmed in an animal experiments, that is, suppression of the p53 pathway increased the lung tumor multiplicity in p53-mutated mice after they were exposed to tobacco smoke.21,22 A predisposition to cancer has been presented in MDM2 overexpressed mice.23 Furthermore, MDM2-rs2279744 SNP was not associated with any clinicopathological data from lung cancer patients. This was a surprising result, but mechanistically it may be rationalized that p53 expression is a result of p53 mutations in most lung cancers. In this case, the p53 gene pathway was already altered and the increased MDM2 expression as a result of MDM2-rs2279744 G/G SNP did not contribute to tumor progression. Indeed, in previous studies, the p53 rs1042522 C-allele SNP was associated with reduced apoptotic potential in lung cancer patients compared to the p53 G-allele, and might modulate lung cancer risk, cancer progression, and/or response to treatment,24–26 indicating that p53 plays an important role in the suppression of lung carcinogenesis. There were a number of limitations in our study. Firstly, the MDM2-TP53 interaction played a pivotal role in regulation of the cell-cycle checkpoint, DNA repair, and apoptotic cell death. A common SNP at p53 rs1042522 has also been found to be of functional significance, with the C-allele having reduced the apoptotic potential compared to the G-allele, which may modulate the lung cancer risk, progression, and/or response to treatment.24–26 Our current data would be much stronger in the prediction of lung cancer risk if we would combine this p53 SNP with MDM2-rs2279744 G/G SNP. Secondly, our current data may not be generalizable to other populations because this is a hospital-based case-control study, and, thus, needs external validation in other populations. Thirdly, our current analyses did not include all epidemiological factors, such as exposure to asbestos. Finally, this was a retrospectively designed study, and the sample size is relatively small; therefore, the results need to be validated by a large-scale and prospective design study.

Conclusion

In conclusion, MDM2-rs2279744 is associated with lung cancer risk in Northeastern Chinese population.

Disclosure

No authors report any conflict of interest.
  26 in total

1.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population.

Authors:  Zhibin Hu; Hongxia Ma; Daru Lu; Ji Qian; Jiannong Zhou; Yijiang Chen; Lin Xu; Xinru Wang; Qingyi Wei; Hongbing Shen
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

2.  MDM2 SNP309 and SNP354 are not associated with lung cancer risk.

Authors:  Sharon R Pine; Leah E Mechanic; Elise D Bowman; Judith A Welsh; Stephen C Chanock; Peter G Shields; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

Review 3.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect.

Authors:  Gareth L Bond; Wenwei Hu; Arnold Levine
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

6.  [Estimation of cancer incidence and mortality in China in 2004-2005].

Authors:  Wan-qing Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2009-09

7.  A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.

Authors:  Nicoleta C Arva; Tamara R Gopen; Kathryn E Talbott; Latoya E Campbell; Agustin Chicas; David E White; Gareth L Bond; Arnold J Levine; Jill Bargonetti
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

8.  Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf.

Authors:  Yian Wang; Zhongqiu Zhang; Ronald Lubet; Ming You
Journal:  Oncogene       Date:  2005-04-21       Impact factor: 9.867

9.  TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis.

Authors:  Lili Yan; Deqiang Zhang; Chengwen Chen; Yumin Mao; Yi Xie; Yao Li; Yan Huang; Baohui Han
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

10.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.

Authors:  Helge Lind; Shanbeh Zienolddiny; Per Olav Ekstrøm; Vidar Skaug; Aage Haugen
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

View more
  1 in total

1.  Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Authors:  Zhuo-Miao Ye; Zi-Qing Tang; Zhe Xu; Qin Zhou; Huan Li
Journal:  Front Public Health       Date:  2022-07-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.